Skip to main content

Table 2 SARS-CoV-2 PCR and Antibody Positivity stratified by data collection period

From: SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis

 

29 May 2020 to 3 Jul 2020

(n = 115)

28 Aug 2020 to 25 Sep 2020

(n = 158)

1 Dec 2020 to 15 Jan 2021

(n = 174)

1 Mar 2021 to 23 Mar 2021

(n = 168)

p value

SARS-CoV-2 PCR

 Positive, N(%)

9 (7.8)

10 (6.3)

5 (2.9)

16 (9.5)

0.085

 95% confidence interval

3.6–14.3%

3.1–11.3%

1–6.6%

5.5–15.0%

SARS-CoV-2 total antibodies

 Positive, N(%)

13 (11.3)

74 (46.8)

80 (46.0)

75 (44.6)

 < 0.001

 95% confidence interval

6.5–18.6%

38.9–54.9%

38.4–53.7%

37.0–52.5%

 Geometric mean, 95% CI (AU/mL)a

31.1 (13.8, 70.0)

29.4 (21.9, 39.4)

26.7 (20.6, 34.8)

13.1 (9.7, 17.8)

  1. p value in bold indicates statistically significant outcome difference across four data collection periods
  2. aGeometric mean concentrations are calculated among participants who tested positive on SARS-CoV-2 total antibodies